Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Dry Eye Clinical Trial

Official title:

A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03226444
• Other study ID #: LOS-001
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 30, 2017
• Est. completion date: December 27, 2019

Study information

• Verified date: January 2020
• Source: TearSolutions, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of two strengths of Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in subjects with a diagnosis of Dry Eye associated with documented Primary Sjögren's Syndrome

Description:

This is a multi-center, randomized, placebo-controlled, double-masked, parallel-group study. Subjects will be randomized into three treatment groups: 0.005%, or 0.01% Lacripep™, or placebo in a 1:1:1 ratio.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 204
• Est. completion date: December 27, 2019
• Est. primary completion date: December 27, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects who meet the following criteria will be selected:

1. Subjects who are age 18 years of age or older at the time of obtaining informed consent.

2. Subjects with a documented prior history or current diagnosis of Primary Sjögren's Syndrome according the American-European Consensus Group Sjögren's Syndrome Criteria (Appendix 4; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note: Subjects who are on systemic (oral) therapy for the treatment of Sjögren's Syndrome must be on stable systemic treatment defined as the same treatment for the immediately prior 90 days.

3. Subjects with a history of dry eye-related ocular symptoms, and who have self-reported use of over the counter ocular wetting agents within the last 120 days.

4. Subjects who meet the following criteria at both screening and Visit 2 (Randomization/Baseline) examinations:

1. FCS total score = 4 and < 15 in the NEI/Industry Workshop scale, (Appendix 6)

2. Symptom Severity score of = 40 using the SANDE questionnaire (Appendix 3)

3. Anesthetized Schirmer test score = 5 mm wetting/5 min

4. LGCS total score = 5 using the NEI/Industry Workshop scale (where 0=no staining) Note: Subjects must meet all 4 criteria and eligible scores for FCS, Anesthetized Schirmer and LGCS must be in at least one eye and it must be in the same eye at the time of the visit.

Exclusion Criteria:

Subjects meeting any of the following criteria at the Visit 1 (Screening) or Visit 2 (Randomization/Baseline) visits will be excluded:

1. Subjects with any active infectious ocular condition.

2. Subjects who are monocular or have a BCVA, using corrective lenses if necessary, of +1.0 logMAR or worse as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS).

3. Subjects with ocular inflammatory conditions (e.g., conjunctivitis, keratitis, anterior blepharitis, etc.) not related to dry eye syndrome.

4. Subjects with clinical evidence of cicatricial ocular surface disease, such as cicatricial ocular pemphigoid or Stevens Johnson syndrome.

5. Subjects who cannot suspend the use of any topical eye medications (including topical cyclosporine) other than the investigational product during the run-in and the study treatment phase.

6. Subjects who have used Restasis® (topical ophthalmic cyclosporine) or Xiidra® (topical ophthalmic lifitegrast) within 14 days prior to Visit 1.

7. Subjects who in the study eye have fluorescein corneal staining (FCS) Total Score = 15 or a Score = 3 in the superior region per the NEI/Industry Workshop scale or subjects who have FCS with diffuse confluent staining, filaments or frank epithelial defects.

8. Subjects who have active or have had an outbreak of herpetic keratitis within 365 days of Visit 1 or subjects who are on chronic oral antivirals for ocular herpetic disease.

9. Subjects who cannot suspend the use of and abstain from contact lens use from the Screening Visit (Visit 1) to the end of the study (Visit 5).

10. Subjects who have a history of collagen vascular disease, auto immune disease or rheumatic disease other than Primary Sjögren's Syndrome (e.g., Lupus, Rheumatoid Arthritis, etc.).

11. Subjects who have a history of or current Anterior Membrane Dystrophy.

12. Subjects who have had a corneal transplant or similar corneal surgery (DALK, DSEK, DMEK, etc.).

13. Subjects who have used or anticipate use of amiodarone.

14. Subjects who within 30 days prior to Visit 1 alter the dose or anticipate alterations to the dose of the following: tetracyclines, Omega 3's or 6's.

15. Subjects who within 60 days prior to Visit 1 and for the duration of the study alter the dose or anticipate alterations to the dose of the following: anticholinergics, antidepressants, oral contraceptives, isotretinoin, oral systemic corticosteroids, oral systemic immunosuppressive agents.

16. Subjects who within 30 days prior to Visit 1 and for the duration of the study use topical ocular antihistamines, ocular, inhaled or intranasal corticosteroids, topical or oral mast cell stabilizers, oral antihistamines, topical or nasal vasoconstrictors, topical ocular NSAIDs, topical ocular antibiotics or serum tears.

17. Subjects who in the study eye have had cauterization of the punctum or alterations to (insertion or removal) punctal plug(s) within the past 14 days prior to Visit 1. Note: If a punctal plug in place at Visit 2 (Randomization/Baseline) and it is dislodged, the plug should be replaced as soon as possible.

18. Subjects who, in the study eye, have had corneal refractive surgery (LASIK, PRK, RK).

19. Subjects who in the study eye, have a history of any operative procedure on the ocular surface or eyelids within 365 days prior to Visit 1 or with a history of intraocular surgery within 90 days prior to Visit 1.

20. Subjects who are pregnant or suspected to be pregnant and subjects who are breastfeeding or intend to breastfeed. Female subjects of childbearing potential are required to have a negative urine pregnancy test at screening, and must agree to use an acceptable method of contraception from the time of signing informed consent until the end of study visit. Medically acceptable contraception methods include intrauterine device; barrier methods such as diaphragm, condom, cap or sponge, used with a spermicide; or hormonal contraception.

21. Subjects with any physical or mental impairment that would preclude participation and the ability to give informed consent.

22. Subjects who have participated in a device or Investigational drug study or clinical trial within 30 days of Visit 1. Participation in another during this study is excluded for the duration of this study.

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes
• Keratoconjunctivitis Sicca
• Primary Sjögren Syndrome
• Sjogren's Syndrome
• Syndrome

Intervention

Drug:
• 0.005% Lacripep
One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
• 0.01% Lacripep
One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
• Placebo
One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.

Locations

Country	Name	City	State
United States	Eye Consultants of Atlanta	Atlanta	Georgia
United States	University of Colorado Department of Ophthalmology	Aurora	Colorado
United States	Milton M. Hom, OD FAAO FACAA (Sc)	Azusa	California
United States	University of California, Berkeley, School of Optometry	Berkeley	California
United States	University of Alabama Eye Center	Birmingham	Alabama
United States	Minnesota Eye Consultants, P.A.	Bloomington	Minnesota
United States	University of Virginia University Eye Center	Charlottesville	Virginia
United States	Abrams Eye Center	Cleveland	Ohio
United States	Ophthalmic Surgeons & Consultants of Ohio; The Eye Center of Columbus	Columbus	Ohio
United States	Bruce A. Segal, MD PA Private Practice	Delray Beach	Florida
United States	Bergstrom Eye Research	Fargo	North Dakota
United States	Orange County Ophthalmology	Garden Grove	California
United States	Lugene Eye Institute	Glendale	California
United States	Cornerstone Eye Care, PA	High Point	North Carolina
United States	Chicago Cornea Consultants, Ltd.	Hoffman Estates	Illinois
United States	Midwest Cornea Associates, LLC	Indianapolis	Indiana
United States	Bowden Eye & Associates	Jacksonville	Florida
United States	Tauber Eye Center	Kansas City	Missouri
United States	The Eye Clinic of Texas, an affiliate of Houston Eye Associates	League City	Texas
United States	Corneal Consultants of Colorado	Littleton	Colorado
United States	The Eye Care Institute	Louisville	Kentucky
United States	UTHSC Department of Ophthalmology	Memphis	Tennessee
United States	Virginia Eye Consultants	Norfolk	Virginia
United States	International Eye Associates, PA	Ormond Beach	Florida
United States	University of Pennsylvania Scheie Eye Institute	Philadelphia	Pennsylvania
United States	Martel Eye Medical Group	Rancho Cordova	California
United States	Black Hills Eye Institute	Rapid City	South Dakota
United States	Vistar Eye Center	Roanoke	Virginia
United States	Ophthalmology Associates	Saint Louis	Missouri
United States	Doctor My Eyes / Stephen Cohen, OD, PC	Scottsdale	Arizona
United States	Schwartz Laser Eye Center	Scottsdale	Arizona
United States	Cornea Consultants of Albany	Slingerlands	New York
United States	Perez Eye Center	Tampa	Florida
United States	Wolstan & Goldberg Eye Associates	Torrance	California
United States	Clinical Eye Research of Boston	Winchester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
TearSolutions, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Fluorescein Corneal Staining total score	Mean change from Baseline/Randomization (Visit 2) to Day 28 (Visit 4) in Fluorescein Corneal Staining (FCS) total score [National Eye Institute (NEI)/Industry Workshop 0-15 scale, 0-3 scale in each of 5 regions] in the study eye.	Changes at Week 4 from Baseline
Secondary	Eye Dryness	Mean change from Baseline/Randomization (Visit 2) to Day 28 (Visit 4) in Eye Dryness Score (0-100 VAS scale, OU) from Individual Symptom Assessments (Instantaneous)	Changes at Week 4 from Baseline
Secondary	Mean Scores for Individual Symptom Assessments (Reflective)	Mean Scores for six Individual Symptom Assessments (Reflective) at Day 28 (Visit 4). The individual reflective symptom assessment is assessed in 6 categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). An anchor in the middle at 50 mm representing their symptom severity at the last visit. The 50 mm scale to the left of the anchor located in the center of the scale will measure worsening symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure improving symptoms (a positive value). The lower score represents greater severity.	Day 28
Secondary	Changes in SANDE-1 to Visit 4	Changes in Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 1 global score from Randomization/Baseline (Visit 2) to Day 28 (Visit 4). SANDE Version 1 questionnaire contains two items measuring the frequency and severity of dry eye symptoms. Each item is assessed on a 100 mm visual analog scale from 0 (Rarely for frequency, Very mild for severity) to 100 mm (All the time for frequency, Very Severe for severity), with higher scores representing greater frequency/severity.	Changes from Baseline to Day 28.
Secondary	Mean Scores SANDE 2	Mean Scores for Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 2 global scores at day 28 (Visit 4). SANDE Version 2 questionnaire contains two items measuring the frequency and severity of dry eye symptoms.The 50 mm scale to the left of the anchor located in the center of the scale will measure improving symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure worsening symptoms (a positive value).	Day 28
Secondary	Changes in Individual Symptom Assessments (Instantaneous)	Changes in each of the 5 additional Individual Symptom Assessment (Instantaneous) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4). The individual instantaneous symptom assessment is a questionnaire that uses a 0-100 mm visual analog scale to rate the severity of each ocular symptom for both eyes (OU). There are six categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). The higher score represents more severe symptoms.	Changes at Baseline to Day 28
Secondary	Changes in LGCS	Changes in Lissamine Green Conjunctival Staining (LGCS) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the study eye.	Changes at Week 4 from Baseline
Secondary	Changes in Anesthetized Schirmer test	Change in Anesthetized Schirmer test from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the study eye.	Changes at Week 4 from Baseline
Secondary	Changes in Tear Film Break Up Time (TFBUT)	Changes in tear film break up time (TFBUT) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the study eye	Changes at Week 4 from Baseline
Secondary	Changes in FCS at Post-Treatment	Changes in Fluorescein Corneal Staining (FCS) from Randomization/Baseline (Visit 2) to the Post-Treatment Follow-Up Visit (day 42) in the study eye. The FCS assessment will be performed for each of the five sections (Central, Inferior, Superior, Temporal, and Nasal) on both eyes (study eye and fellow eye) using the National Eye Institute (NEI)/Industry Workshop scale. The staining in each of the 5 sections of the cornea is evaluated per the NEI score: Grades of 0, 1, 2, and 3 with higher grades representing greater severity.	Baseline to Visit 5 / Day 42
Secondary	Changes in SANDE-1 to Visit 5	Changes in Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 1 global score from Randomization/Baseline (Visit 2) to the Post Treatment Follow-up visit (Day 42). SANDE Version 1 questionnaire contains two items measuring the frequency and severity of dry eye symptoms. Each item is assessed on a 100 mm visual analog scale from 0 (Rarely for frequency, Very mild for severity) to 100 mm (All the time for frequency, Very Severe for severity), with higher scores representing greater frequency/severity.	Baseline to Visit 5 / Day 42
Secondary	Changes in Individual Symptom Assessments (Instantaneous) from Baseline Visit 5	Changes in six Individual Symptoms (Instantaneous) from Randomization/Baseline (Visit 2) to the Post-Treatment Follow-up Visit (Day 42). The individual instantaneous symptom assessment is a questionnaire that uses a 0-100 mm visual analog scale to rate the severity of each ocular symptom. There are six categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). The higher score represents more severe symptoms.	Baseline to Visit 5
Secondary	Mean Scores for SANDE-2	Mean Scores for Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 2 global score at the Post-Treatment Follow-Up Visit (Day 42). SANDE Version 2 questionnaire contains two items measuring the frequency and severity of dry eye symptoms.The 50 mm scale to the left of the anchor located in the center of the scale will measure improving symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure worsening symptoms (a positive value).	Visit 5 / Day 42
Secondary	Mean Scores for six Individual Symptom Assessments (Reflective)	Mean Scores for six Individual Symptom Assessments (Reflective) at the Post-Treatment Follow-Up Visit (Day 42). The individual reflective symptom assessment is assessed in 6 categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). The 50 mm scale to the left of the anchor located in the center of the scale will measure worsening symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure improving symptoms (a positive value).	Visit 5 / Day 42
Secondary	Changes in FCS	Mean change from Baseline/Randomization (Visit 2) to Day 28 (Visit 4) in Fluorescein Corneal Staining (FCS) total score [National Eye Institute (NEI)/Industry Workshop 0-15 scale, 0-3 scale in each of 5 regions] in the qualifying fellow eye.	Baseline to Day 28
Secondary	Changes in LCGS Anesthetized Schirmer test, TFBUT	Changes in Lissamine Green Conjunctival Staining (LCGS) Anesthetized Schirmer test, tear film break up time (TFBUT) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the qualifying fellow eye.	Baseline to Day 28